| 1.18 -0.13 (-9.92%) | 07-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.59 |
1-year : | 1.75 |
| Resists | First : | 1.36 |
Second : | 1.5 |
| Pivot price | 1.21 |
|||
| Supports | First : | 1.14 | Second : | 0.95 |
| MAs | MA(5) : | 1.24 |
MA(20) : | 1.23 |
| MA(100) : | 1.61 |
MA(250) : | 2.24 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 54.5 |
D(3) : | 53.5 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 4.98 | Low : | 1.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FLNA ] has closed above bottom band by 24.5%. Bollinger Bands are 64.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.38 |
| Low: | 1.16 - 1.17 | 1.17 - 1.18 |
| Close: | 1.17 - 1.18 | 1.18 - 1.19 |
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Mon, 06 Jul 2026
MSN Money - MSN
Fri, 03 Jul 2026
FLNA Should I Buy - Intellectia AI
Sun, 28 Jun 2026
FLNA - Filana Therapeutics Inc Short Interest - Finviz
Fri, 26 Jun 2026
Filana Therapeutics, Inc. Actuals & Estimates (NASDAQ:FLNA) - TradingView
Mon, 15 Jun 2026
Filana Therapeutics (FLNA) investors back directors, plan changes and auditor - Stock Titan
Thu, 07 May 2026
FLNA SEC Filings - Filana Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 11 (%) |
| Held by Institutions | 28.7 (%) |
| Shares Short | 6,580 (K) |
| Shares Short P.Month | 6,690 (K) |
| EPS | -1.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25 % |
| Return on Equity (ttm) | -79.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.37 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | 16 (M) |
| PE Ratio | -0.74 |
| PEG Ratio | 1.6 |
| Price to Book value | 0.83 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.92 |
| Dividend | 5.25 |
| Forward Dividend | 0 |
| Dividend Yield | 444.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|